For instance, the CANTOS trial demonstrated the efficacy of targeting inflammation in atherosclerosis with an anti-interleukin-1β antibody and found a reduction in cardiovascular events.52 In addition, the use of mepolizumab, an antibody against interleukin-5, in eosinophilic myocarditis demonstrates the feasibility of targeted immunotherapies.53 However, patient response variability and potential side effects call for careful development and optimization of these therapies. The gene discussed is IL5; the disease is atherosclerosis.